How likely are COVID-19 interventions to benefit the sickest patients?

Perner, Anders; Tirupakuzhi Vijayaraghavan, Bharath Kumar; Venkatesh, Balasubramanian

Perner, Anders; Tirupakuzhi Vijayaraghavan, Bharath Kumar; Venkatesh, Balasubramanian.

Perner A; Department of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. anders.perner@rh.regionh.dk.
Tirupakuzhi Vijayaraghavan BK; Department of Critical Care, Apollo Hospitals, Chennai, India.
Venkatesh B; The George Institute for Global Health, Sydney, Australia.

Intensive Care Med ; 46(7): 1441-1444, 2020 Jul.

Article in English | MEDLINE | ID: covidwho-591819

Subject(s)

Antiviral Agents/therapeutic use; Betacoronavirus; Coronavirus Infections/drug therapy; Pneumonia, Viral/drug therapy; Adrenal Cortex Hormones/therapeutic use; COVID-19; Coronavirus Infections/epidemiology; Coronavirus Infections/therapy; Critical Illness/therapy; Humans; Immunization, Passive; Immunotherapy; Interferons/therapeutic use; Pandemics; Pneumonia, Viral/epidemiology; Pneumonia, Viral/therapy; SARS-CoV-2; COVID-19 Serotherapy

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Coronavirus Infections / Betacoronavirus Type of study: Experimental Studies / Observational study Limits: Humans Language: English Journal: Intensive Care Med Year: 2020 Document Type: Article Affiliation country: S00134-020-06131-1

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google